Atlas Trials

CD19-Specific T Cells Post AlloSCT

Clinical trial NCT03579888 · TERMINATED

Trial details

NCT number
NCT03579888
Sponsor
M.D. Anderson Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A RearrangedRecurrent B Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Mantle Cell LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Ph-Like Acute Lymphoblastic LeukemiaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory B Acute Lymphoblastic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Start date
2020-06-26
Primary completion
2021-05-27
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.